{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:28:23Z","timestamp":1777865303256,"version":"3.51.4"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["273319"],"award-info":[{"award-number":["273319"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["275873"],"award-info":[{"award-number":["275873"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["APVV-19-0189"],"award-info":[{"award-number":["APVV-19-0189"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009123","name":"Norges Teknisk-Naturvitenskapelige Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009123","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018883","name":"Maurice Wilkins Centre for Molecular Biodiscovery","doi-asserted-by":"publisher","award":["4531"],"award-info":[{"award-number":["4531"]}],"id":[{"id":"10.13039\/501100018883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001518","name":"Maurice and Phyllis Paykel Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001518","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118622","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:05:54Z","timestamp":1769792754000},"page":"118622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["New antitubercular pretomanid analogues as potent payloads in polymeric micelles: Leveraging zebrafish assays to accelerate lead optimisation"],"prefix":"10.1016","volume":"307","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-8559","authenticated-orcid":false,"given":"Andrew M.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils-J\u00f8rgen K.","family":"Dal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Boldrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelia","family":"Alonso-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Johann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Speth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cioetto-Mazzab\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"P\u00e1l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Kordul\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Barz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Fenaroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Denny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118622_bib1","first-page":"515","volume":"65","author":"Herzog","year":"1998","journal-title":"History of Tuberculosis, Respiration"},{"key":"10.1016\/j.ejmech.2026.118622_bib2","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1021\/acs.jmedchem.2c00227","article-title":"Tuberculosis drug discovery: challenges and new horizons","volume":"65","author":"Fernandes","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib3","series-title":"Global Tuberculosis Report 2024","year":"2024"},{"key":"10.1016\/j.ejmech.2026.118622_bib4","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3390\/vaccines11081304","article-title":"Next-generation TB vaccines: progress, challenges, and prospects","volume":"11","author":"Zhuang","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ejmech.2026.118622_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","article-title":"Anti-tuberculosis treatment strategies and drug development: challenges and priorities","volume":"20","author":"Dartois","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118622_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107140","article-title":"Tuberculosis and diabetes mellitus: the complexity of the comorbid interactions","volume":"146","author":"Boadu","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118622_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2025.107876","article-title":"Tuberculosis and HIV coinfection: progress and challenges towards reducing incidence and mortality","volume":"155","author":"Sossen","year":"2025","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118622_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","article-title":"Multidrug-resistant tuberculosis","volume":"10","author":"Dheda","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2026.118622_bib9","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3390\/app10062153","article-title":"Drug-resistant tuberculosis 2020: where we stand","volume":"10","author":"Iacobino","year":"2020","journal-title":"Appl. Sci."},{"key":"10.1016\/j.ejmech.2026.118622_bib10","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.15.04004","article-title":"Health system and environmental factors affecting global progress towards achieving End TB targets between 2015 and 2020","volume":"15","author":"Wolde","year":"2025","journal-title":"J. Glob. Health"},{"key":"10.1016\/j.ejmech.2026.118622_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00180-19","article-title":"The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives","volume":"35","author":"Dookie","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2026.118622_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118622_bib14","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: first approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118622_bib15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"ZeNix trial team, bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118622_bib16","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2026.118622_bib17","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijid.2023.03.013","article-title":"Update of drug-resistant tuberculosis treatment guidelines: a turning point","volume":"130","author":"Vanino","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118622_bib18","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118622_bib19","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1038\/s41467-023-39300-z","article-title":"DprE2 is a molecular target of the antitubercular nitroimidazole compounds pretomanid and delamanid","volume":"14","author":"Abrahams","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118622_bib20","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.1164571","article-title":"PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release","volume":"322","author":"Singh","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118622_bib21","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1021\/jm101288t","article-title":"Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"53","author":"Kmentova","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib22","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1021\/jm501608q","article-title":"Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"58","author":"Palmer","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1128\/AAC.03823-14","article-title":"In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis","volume":"59","author":"Upton","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118622_bib24","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1080\/00498254.2017.1375168","article-title":"The downfall of TBA-354 - a possible explanation for its neurotoxicity via mass spectrometric imaging","volume":"48","author":"Ntshangase","year":"2018","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejmech.2026.118622_bib25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.drudis.2017.01.011","article-title":"How can nanoparticles contribute to antituberculosis therapy?","volume":"22","author":"Costa-Gouveia","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118622_bib26","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrmicro2437","article-title":"Nanobead-based interventions for the treatment and prevention of tuberculosis","volume":"8","author":"Griffiths","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118622_bib27","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/ph16101360","article-title":"Nanocarriers in tuberculosis treatment: challenges and delivery strategies","volume":"16","author":"Kumar","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.118622_bib28","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1186\/s12951-023-02156-y","article-title":"Advanced drug delivery and therapeutic strategies for tuberculosis treatment","volume":"21","author":"Nair","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejmech.2026.118622_bib29","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1021\/acsbiomaterials.1c00807","article-title":"Mesoporous silica nanoparticles improve oral delivery of antitubercular bicyclic nitroimidazoles","volume":"8","author":"Ang","year":"2022","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.ejmech.2026.118622_bib30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jconrel.2023.01.037","article-title":"\u03a0-\u03a0 interactions stabilize PeptoMicelle-based formulations of pretomanid derivatives leading to promising therapy against tuberculosis in zebrafish and mouse models","volume":"354","author":"Dal","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejmech.2026.118622_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.progpolymsci.2024.101889","article-title":"Polypept(o)ides \u2013 origins, synthesis, applications and future directions","volume":"158","author":"Bauer","year":"2024","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.ejmech.2026.118622_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1462-5822.2008.01133.x","article-title":"Comparative pathogenesis of Mycobacterium marinum and Mycobacterium tuberculosis","volume":"10","author":"Tobin","year":"2008","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118622_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016779","article-title":"A high-throughput screen for tuberculosis progression","volume":"6","author":"Carvalho","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118622_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2011.02.022","article-title":"Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism","volume":"145","author":"Adams","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118622_bib35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.celrep.2012.06.008","article-title":"An in vivo platform for rapid high-throughput antitubercular drug discovery","volume":"2","author":"Takaki","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118622_bib36","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1128\/AAC.03588-14","article-title":"Testing tuberculosis drug efficacy in a zebrafish high-throughput translational medicine screen","volume":"59","author":"Ordas","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118622_bib37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/jac\/dkw421","article-title":"Screening of anti-mycobacterial compounds in a naturally infected zebrafish larvae model","volume":"72","author":"Dalton","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.118622_bib38","article-title":"The zebrafish embryo as an in vivo model for screening nanoparticle-formulated lipophilic anti-tuberculosis compounds","volume":"15","author":"Dal","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ejmech.2026.118622_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104163","article-title":"Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis","volume":"29","author":"Antunes","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118622_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1021\/acs.chemrestox.9b00335","article-title":"Use of zebrafish in drug discovery toxicology","volume":"33","author":"Cassar","year":"2020","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2026.118622_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/bdrc.20206","article-title":"Zebrafish embryos and larvae: a new generation of disease models and drug screens","volume":"93","author":"Ali","year":"2011","journal-title":"Birth Defects Res. (Part C)"},{"key":"10.1016\/j.ejmech.2026.118622_bib42","doi-asserted-by":"crossref","first-page":"dmm049145","DOI":"10.1242\/dmm.049145","article-title":"An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor","volume":"14","author":"Habjan","year":"2021","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ejmech.2026.118622_bib43","doi-asserted-by":"crossref","first-page":"16651","DOI":"10.1021\/acs.jmedchem.2c01493","article-title":"Tricyclic spirolactams kill mycobacteria in vitro and in vivo by inhibiting type II NADH dehydrogenases","volume":"65","author":"Dam","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib44","doi-asserted-by":"crossref","first-page":"14927","DOI":"10.1021\/acs.jmedchem.4c00441","article-title":"Design, synthesis, and evaluation of the antitubercular activity of 5-phenyl substituted-5, 6-dihydropyrido[2, 3-d]pyrimidine-4, 7(3H, 8H)-dione compounds","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib45","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/emmm.201303575","article-title":"Towards a new combination therapy for tuberculosis with next generation benzothiazinones","volume":"6","author":"Makarov","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2026.118622_bib46","first-page":"e43","article-title":"Zebrafish in pharmaceutical industry research: finding the best fit","volume":"10","author":"Fleming","year":"2013","journal-title":"Drug Discov. Today: Dis. Models"},{"key":"10.1016\/j.ejmech.2026.118622_bib47","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1111\/bph.15247","article-title":"Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans","volume":"177","author":"van Wijk","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118622_bib48","doi-asserted-by":"crossref","first-page":"fuae011","DOI":"10.1093\/femsre\/fuae011","article-title":"Diving into drug-screening: zebrafish embryos as an in vivo platform for antimicrobial drug discovery and assessment","volume":"48","author":"Habjan","year":"2024","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2026.118622_bib49","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.102.039255","article-title":"Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs","volume":"303","author":"Mahar Doan","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2026.118622_bib50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.str.2011.11.001","article-title":"Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824","volume":"20","author":"Cellitti","year":"2012","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.118622_bib51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1742-4658.2011.08404.x","article-title":"Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles","volume":"279","author":"Gurumurthy","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2026.118622_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008287","article-title":"Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering","volume":"16","author":"Lee","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2026.118622_bib53","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1021\/jm801087e","article-title":"Synthesis, reduction potentials, and antitubercular activity of ring A\/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"52","author":"Thompson","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib54","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4155\/fmc.11.90","article-title":"Nitroimidazoles for the treatment of TB: past, present and future","volume":"3","author":"Mukherjee","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib55","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bmcl.2017.10.067","article-title":"Assessment of a pretomanid analogue library for African trypanosomiasis: hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides","volume":"28","author":"Thompson","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118622_bib56","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijpharm.2004.10.007","article-title":"Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier","volume":"288","author":"Wang","year":"2005","journal-title":"Int. J. Pharm"},{"key":"10.1016\/j.ejmech.2026.118622_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105222","article-title":"Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis","volume":"9","author":"Lakshminarayana","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118622_bib58","series-title":"Nitro-[2,1-b]imidazopyran compounds and antibacterial uses thereof","author":"Baker","year":"2000"},{"key":"10.1016\/j.ejmech.2026.118622_bib59","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1021\/acsmedchemlett.7b00356","article-title":"Antitubercular nitroimidazoles revisited: synthesis and activity of the authentic 3-nitro isomer of pretomanid","volume":"8","author":"Thompson","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118622_bib60","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1021\/jm901207n","article-title":"Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"53","author":"Palmer","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib61","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1021\/jm200377r","article-title":"Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"54","author":"Thompson","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib62","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1021\/acs.jmedchem.7b01256","article-title":"Synthesis and structure-activity relationships of the novel antimalarials 5-pyridinyl-4(1H)-pyridones","volume":"61","author":"Bueno","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib63","series-title":"Metalloenzyme Inhibitor Compounds, Patent WO 2012\/177728 A1","author":"Hoekstra","year":"2012"},{"key":"10.1016\/j.ejmech.2026.118622_bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1039\/C6SC02118B","article-title":"Site-selective Suzuki-Miyaura coupling of heteroaryl halides - understanding the trends for pharmaceutically important classes","volume":"8","author":"Almond-Thynne","year":"2017","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.118622_bib65","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.1021\/acs.biochem.6b00683","article-title":"Hydrophobic shielding drives catalysis of hydride transfer in a family of F420H2-dependent enzymes","volume":"55","author":"Mohamed","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.118622_bib66","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1128\/AAC.00308-15","article-title":"Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis","volume":"59","author":"Haver","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118622_bib67","article-title":"Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis","volume":"65","author":"Rifat","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118622_bib68","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41467-022-29832-1","article-title":"CinA mediates multidrug tolerance in Mycobacterium tuberculosis","volume":"13","author":"Kreutzfeldt","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118622_bib69","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.2147\/DDDT.S281639","article-title":"Profiling pretomanid as a therapeutic option for TB infection: evidence to date","volume":"15","author":"Stancil","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejmech.2026.118622_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/jmm.0.000198","article-title":"Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria","volume":"65","author":"Soni","year":"2016","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118622_bib71","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2147\/IDR.S240716","article-title":"Comparison of in vitro susceptibility of mycobacteria against PA-824 to identify key residues of Ddn, the deazoflavin-dependent nitroreductase from Mycobacterium tuberculosis","volume":"13","author":"Zhang","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.ejmech.2026.118622_bib72","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1073\/pnas.0508392103","article-title":"Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis","volume":"103","author":"Manjunatha","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118622_bib73","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1476-5381.2010.01040.x","article-title":"Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver","volume":"162","author":"Dogra","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118622_bib74","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1038\/s41598-018-23110-1","article-title":"Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)","volume":"8","author":"Baptista","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118622_bib75","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00663-19","article-title":"Common variants in the glycerol kinase gene reduce tuberculosis drug efficacy","volume":"10","author":"Bellerose","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.ejmech.2026.118622_bib76","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/nar\/gkac1173","article-title":"SigH stress response mediates killing of Mycobacterium tuberculosis by activating nitronaphthofuran prodrugs via induction of Mrx2 expression","volume":"51","author":"Cioetto-Mazzab\u00f2","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118622_bib77","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1021\/acs.jmedchem.8b00077","article-title":"Lipophilic efficiency as an important metric in drug design","volume":"61","author":"Johnson","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094462","article-title":"Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis","volume":"9","author":"Wallis","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118622_bib79","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(25)00213-0","article-title":"PanACEA consortium, Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial","volume":"25","author":"Heinrich","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118622_bib80","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1039\/D2BM01835G","article-title":"Subcellular localization and therapeutic efficacy of polymeric micellar nanoparticles encapsulating bedaquiline for tuberculosis treatment in zebrafish","volume":"11","author":"Bhandari","year":"2023","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ejmech.2026.118622_bib81","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13318-013-0162-9","article-title":"The use of a prodrug approach to minimize potential CNS exposure of next generation quinoline methanols while maintaining efficacy in in vivo animal models","volume":"39","author":"Sousa","year":"2014","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2026.118622_bib82","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","article-title":"Rational use of in vitro P-glycoprotein assays in drug discovery","volume":"299","author":"Polli","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2026.118622_bib83","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejpb.2016.02.002","article-title":"Effects of gastric pH on oral drug absorption: in vitro assessment using a dissolution\/permeation system reflecting the gastric dissolution process","volume":"101","author":"Kataoka","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejmech.2026.118622_bib84","article-title":"CRISPR screening and comparative LC-MS analysis identify genes mediating efficacy of delamanid and pretomanid against Mycobacterium tuberculosis","volume":"11","author":"Yan","year":"2024","journal-title":"Adv. Sci. (Weinh)."},{"key":"10.1016\/j.ejmech.2026.118622_bib85","doi-asserted-by":"crossref","first-page":"8115","DOI":"10.1021\/acs.jmedchem.9b00912","article-title":"Development of 3,5-dinitrophenyl-containing 1,2,4-triazoles and their trifluoromethyl analogues as highly efficient antitubercular agents inhibiting decaprenylphosphoryl-\u03b2-D-ribofuranose 2\u2032-oxidase","volume":"62","author":"Karabanovich","year":"2019","journal-title":"J. Med. Chem."},{"issue":"Part 2","key":"10.1016\/j.ejmech.2026.118622_bib86","article-title":"Advancing the antituberculosis activity of nitropicolinic acids and amides","volume":"302","author":"Thompson","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib87","article-title":"Genetic manipulation of Mycobacterium tuberculosis","author":"Larsen","year":"2007","journal-title":"Curr. Protoc. Microbiol. Chapter 10, Unit 10A.2"},{"key":"10.1016\/j.ejmech.2026.118622_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1013474","article-title":"Genome-wide phenotypic insights into mycobacterial virulence using Drosophila melanogaster","volume":"21","author":"Sivakumar","year":"2025","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2026.118622_bib89","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1021\/acs.jmedchem.5b01699","article-title":"Repositioning antitubercular 6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for neglected tropical diseases: structure\u2013activity studies on a preclinical candidate for visceral leishmaniasis","volume":"59","author":"Thompson","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib90","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1021\/acs.jmedchem.3c00925","article-title":"Both nitro groups are essential for high antitubercular activity of 3,5-dinitrobenzylsulfanyl tetrazoles and 1,3,4-oxadiazoles through the deazaflavin-dependent nitroreductase activation pathway","volume":"67","author":"Karabanovich","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118622_bib91","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1038\/s41467-024-48269-2","article-title":"Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy","volume":"15","author":"Mistretta","year":"2024","journal-title":"Nat. Commun."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600067X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600067X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:11:09Z","timestamp":1777529469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342600067X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":90,"alternative-id":["S022352342600067X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118622","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New antitubercular pretomanid analogues as potent payloads in polymeric micelles: Leveraging zebrafish assays to accelerate lead optimisation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118622"}}